Log in to search using one of your social media accounts:

 

NICE approves breakthrough breast cancer drugs
New class of cancer treatment drugs approved for NHS Related items fromOnMedica The genetics of breast cancer Ovarian cancer drug may help stall breast cancer Experts recommend anastrozole for postmenopausal women with family history of breast cancer (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 16, 2017 Category: UK Health Source Type: news

Genetic test may help fight secondary breast cancer
Study shows benefits of using bone strengthening drugs Related items fromOnMedica Big data advances breast cancer research by ‘decades’ Experts recommend anastrozole for postmenopausal women with family history of breast cancer Women with incurable breast cancer receiving insufficient care Research reveals age-specific cancer risk with BRCA1/2 The genetics of breast cancer (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 24, 2017 Category: UK Health Source Type: news

NICE set to approve trastuzumab emtansine for breast cancer
NHS England will routinely fund Kadcyla for people with advanced HER-2 positive cancer Related items fromOnMedica Ovarian cancer drug may help stall breast cancer The medicine price debate Breast cancer drug ‘too costly’ for NHS Experts recommend anastrozole for postmenopausal women with family history of breast cancer Cancer-preventing drugs (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 16, 2017 Category: UK Health Source Type: news

Ovarian cancer drug may help stall breast cancer
Trial results with olaparib are ‘encouraging’ Related items fromOnMedica Breast cancer Big data advances breast cancer research by ‘decades’ Women with incurable breast cancer receiving insufficient care Cancer-preventing drugs Experts recommend anastrozole for postmenopausal women with family history of breast cancer (Source: OnMedica Latest News)
Source: OnMedica Latest News - June 5, 2017 Category: UK Health Source Type: news

NICE: anastrozole for some women at risk of breast cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2017 Category: Drugs & Pharmacology Source Type: news

Experts recommend anastrozole for postmenopausal women with family history of breast cancer
Doctors should offer it to women at moderate risk of breast cancer Related items fromOnMedica Fertility treatments may impact on breast cancer risk Work needed to boost GPs ’ knowledge of cancer drug Cancer-preventing drugs (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 23, 2017 Category: UK Health Source Type: news

Arimidex (Anastrozole) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 17, 2017 Category: Drugs & Pharmacology Source Type: news

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
This research has been highlighted as a practice changing update by DynaMed Plus. It concludes that Fulvestrant has superior efficacy and is a preferred treatment option for patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not received previous endocrine therapy compared with a third-generation aromatase inhibitor, a standard of care for first-line treatment of these patients (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 4, 2017 Category: Consumer Health News Source Type: news

NHS to offer breast cancer prevention treatment pill for 4p-a-day
Prescribing watchdogs the National Institute for Health and Care Excellence said the drug, anastrozole, should be available to women who are over 50 and deemed to have a high risk. (Source: the Mail online | Health)
Source: the Mail online | Health - December 4, 2016 Category: Consumer Health News Source Type: news

Anastrozole recommended for prevention of breast cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 30, 2016 Category: Drugs & Pharmacology Source Type: news

Older DCIS Patients Have Low Rates of Tamoxifen, AI Usage
The initiation of and adherence to tamoxifen or aromatase inhibitors (AIs) such as anastrozole is low among older women with estrogen receptor-positive ductal carcinoma in situ. (Source: CancerNetwork)
Source: CancerNetwork - November 1, 2016 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

ASCO: Clinical and QOL Benefits With Arimidex in Endometrial Ca (CME/CE)
(MedPage Today) -- 44% clinical benefit rate, median PFS of 3.2 months in recurrent disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 15, 2016 Category: Hematology Source Type: news

AstraZeneca finds faslodex better than arimidex in treating metastatic breast cancer
AstraZeneca has found that faslodex 500mg (fulvestrant) is demonstrating better results than arimidex 1mg (anastrozole) while treating locally-advanced or metastatic breast cancer in post-menopausal women, who have not had prior hormonal treatment fo… (Source: Drug Development Technology)
Source: Drug Development Technology - May 30, 2016 Category: Pharmaceuticals Source Type: news

Which Medication is More Cost Effective?
Tamoxifen and Arimidex are two hormone therapy drugs that are commonly prescribed to prevent recurrence of hormone-sensitive breast cancer. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 15, 2016 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Prioritizing Patients Over Profits
Imagine a pharmaceutical company that distributes all profits to patient support and medical research... Enter For Benefit Medicines (FBM), established by Dr Barry Frost, in partnership with John Hurley. Frost holds a PhD in pharmacology and has spent 35 years working for four different major pharmaceutical companies. With a rich and varied experience in pharma, it has been the ‘for benefit’ model that has interested him most over the past few years. After reading an article in the Harvard Business Review (November 2011 edition) entitled “The For Benefit Enterprise,” Frost was intrigued by...
Source: EyeForPharma - January 25, 2016 Category: Pharmaceuticals Authors: Dr Nicola Davies Source Type: news

Drug Trials in DCIS Almost a Wash (CME/CE)
(MedPage Today) -- Patient preference in side effects likely to influence choice of Arimidex or Nolvadex (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - December 14, 2015 Category: Journals (General) Source Type: news

Two Drugs Equal in Preventing Early Breast Cancer's Return: Study
Women with ductal carcinoma in situ had similar outcomes with tamoxifen, anastrozole (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - December 12, 2015 Category: Cancer & Oncology Source Type: news

AI vs Tamoxifen for DCIS? A Toss-up, Unless…AI vs Tamoxifen for DCIS? A Toss-up, Unless…
Both anastrozole and tamoxifen were effective at preventing recurrence of breast cancer in postmenopausal women with ductal carcinoma in situ. Age, toxicities should drive choice, say investigators. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Anastrozole is as effective as current breast cancer drugs with fewer side effects
Post-menopausal women taking anastrozole experienced fewer womb, ovarian and skin cancers and fewer gynaecological symptoms, according to a study led by Queen Mary University. (Source: the Mail online | Health)
Source: the Mail online | Health - December 11, 2015 Category: Consumer Health News Source Type: news

For women taking 2 leading breast cancer drugs, symptoms tend to vary by patient’s age
UCLA Jonsson Comprehensive Cancer Center Dr. Patricia Ganz A study of two leading breast cancer drugs has determined that the breast cancer symptoms women experience while taking those drugs — and the severity of those symptoms — tend to vary based on the patients’ ages. The findings could be an important step toward personalized medicine for women with breast cancer, said Dr. Patricia Ganz, director of the UCLA Jonsson Comprehensive Cancer Center’s Prevention and Control Research program and the study’s first author. The study examined data for 1,193 postmenopausal women with a type of breas...
Source: UCLA Newsroom: Health Sciences - December 11, 2015 Category: Universities & Medical Training Source Type: news

Drug provides another treatment option for an early form of breast cancer
The drug anastrozole is effective in treating an early form of breast cancer, according to a clinical trial. The results of the trial show that anastrozole is as effective as tamoxifen for this type of breast cancer and could offer a new treatment option for post-menopausal women. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 11, 2015 Category: Science Source Type: news

Two Drugs Equal in Preventing Early Breast Cancer’s Return: Study
Women with ductal carcinoma in situ had similar outcomes with tamoxifen, anastrozole (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 11, 2015 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Oncology, Pharmacy, News, Source Type: news

Two Drugs Equal in Preventing Early Breast Cancer's Return: Study
Women with ductal carcinoma in situ had similar outcomes with tamoxifen, anastrozole (Source: WebMD Health)
Source: WebMD Health - December 11, 2015 Category: Consumer Health News Source Type: news

Drug provides another treatment option for an early form of breast cancer
(Queen Mary, University of London) The drug anastrozole is effective in treating an early form of breast cancer, according to a clinical trial led by Queen Mary University of London. The results of the IBIS-II DCIS trial show that anastrozole is as effective as tamoxifen for this type of breast cancer and could offer a new treatment option for post-menopausal women. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2015 Category: Cancer & Oncology Source Type: news

DCIS patients receiving anastrozole reported symptoms different from those receiving tamoxifen
(American Association for Cancer Research) Analysis of patient-reported outcomes (PRO), a secondary endpoint of the phase III, NSABP B-35 clinical trial, in which anastrazole and tamoxifen were compared in postmenopausal women with ductal carcinoma in-situ (DCIS) who underwent lumpectomy plus radiotherapy, found that there were no differences in outcomes related to quality of life but some differences in outcomes related to symptoms in the two treatment groups, according to data presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2015 Category: Cancer & Oncology Source Type: news

No significant differences in recurrence rates among women with DCIS taking anastrozole or tamoxifen
(American Association for Cancer Research) Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for five years after surgery, but women in the two groups had different side effects, according to results from the phase III IBIS-II DCIS clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2015 Category: Cancer & Oncology Source Type: news

Breast Cancer Survival Improved With Arimidex (CME/CE)
(MedPage Today) -- But aromatase inhibitor may not best tamoxifen in older women (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 2, 2015 Category: Geriatrics Source Type: news

ASCO: Arimidex Ups 10-Year Survival Rate in DCIS (CME/CE)
(MedPage Today) -- But aromatase inhibitor may not best tamoxifen in older women (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 1, 2015 Category: Geriatrics Source Type: news

Anastrozole prevents recurrence more than tamoxifen in some with noninvasive breast cancer
Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen. The benefit reported in this trial appeared later in follow up of the women in the study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 1, 2015 Category: Science Source Type: news

Anastrozole prevents recurrence more than tamoxifen in some with noninvasive breast cancer
(Loyola University Health System) Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen. These findings were presented today at the 2015 ASCO Annual Meeting in Chicago. The benefit reported in this trial appeared later in follow up of the women in the study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 30, 2015 Category: Cancer & Oncology Source Type: news

Some 'Benign' Breast Masses Pose Greater Cancer Risk Than We Thought
By Gene Emery (Reuters Health) - A type of "benign" mass found in the breast tissue of about 100,000 U.S. women each year poses a greater risk of cancer than previously thought, according to a new review. The mass is classified as atypical hyperplasia, or atypia. Most women who have it - and one out of 10 women who have a breast biopsy do - are usually told that their test result was benign, even though their cells seemed to be exhibiting some early characteristics of a tumor. Doctors may tell those women that they face an above-average risk of cancer so they need to be followed more closely,...
Source: Healthy Living - The Huffington Post - December 31, 2014 Category: Consumer Health News Source Type: news

Fulvestrant Survival Advantage in Advanced Breast CancerFulvestrant Survival Advantage in Advanced Breast Cancer
New survival data from the FIRST trial show a survival advantage for the injectable fulvestrant over the standard of care, oral anastrozole. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

anastrozole (Arimidex)
Title: anastrozole (Arimidex)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 10/3/2014 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 3, 2014 Category: Drugs & Pharmacology Source Type: news

One million women denied 7p breast cancer drug that can halve chance of developing disease
One million women have been denied pills that could reduce chances of developing breast cancer. Tamoxifen, Raloxifene and Anastrozole have not been licensed for preventative use. (Source: the Mail online | Health)
Source: the Mail online | Health - September 29, 2014 Category: Consumer Health News Source Type: news

One million women denied the 7p breast cancer drug that can halve chance of developing disease because of red tape
One million women have been denied pills that could reduce chances of developing breast cancer. Tamoxifen, Raloxifene and Anastrozole have not been licensed for preventative use. (Source: the Mail online | Health)
Source: the Mail online | Health - September 29, 2014 Category: Consumer Health News Source Type: news

Arimidex – Anastrozole – Aromatase...
Arimidex helps prevent the production of estrogen, a hormone that fuels many breast cancer tumors. It is considered a hormonal treatment, and can help prevent recurrence of breast cancer in postmenopausal women. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - May 5, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Arimidex: Top Drug for Breast Ca Prevention?
SAN ANTONIO (MedPage Today) -- Should anastrozole (Arimidex) be the first choice in pharmacologic primary prevention of breast cancer, based on IBIS-II trial results presented here? No, said most experts. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 17, 2013 Category: Hematology Source Type: news

Exercise can reduce drug-related joint pain in breast cancer patients, study shows
Breast cancer survivors taking aromatase inhibitors (AIs) such as anastrozole, letrozole, and exemestane experienced a reduction in joint pain if they exercised while on treatment, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.Five years of AI use after surgery or other primary treatment is recommended for postmenopausal women diagnosed with stages 1-3 hormone receptor-positive breast cancers, which account for nearly 70 percent of all newly diagnosed breast cancer cases. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 17, 2013 Category: Consumer Health News Tags: Pain / Anesthetics Source Type: news

Antihormone therapy anastrozole may provide new option for breast cancer prevention (EurekAlert, 12 December 2013)
Data from the International Breast Cancer Intervention Study II (IBIS-II) Prevention trial presented at the 2013 San Antonio Breast Cancer Symposium, and published in The Lancet, investigates the use of aromatase inhibitor anastrozole in the prevention of hormone receptor-positive breast cancer in high risk women. Full article (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 13, 2013 Category: Endocrinology Source Type: news

Breast cancer drug halves cases in high-risk women
A large landmark study funded by Cancer Research UK has found that the breast cancer drug anastrozole can halve the chances of developing the disease in high-risk women.The results of the IBIS II trial, led by Queen Mary University of London and published online in the The Lancet this week, show that in nearly 4,000 post-menopausal women at high risk of breast cancer, taking anastrozole for 5 years cut cases by 53%, compared with a placebo. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Anastrozole may cut breast cancer risk
Conclusion Overall, the study provides solid and believable evidence that anastrozole can reduce the number of new cases of breast cancer in postmenopausal women at higher than average risk of developing breast cancer. The study has many strengths, including its large sample size and robust study design. However, the study also has limitations to note. The results only apply to a specific group of postmenopausal women at a higher than average risk of developing breast cancer. "Higher risk" was defined using a number of very specific criteria. This means the results are not applicable to other groups of post...
Source: NHS News Feed - December 13, 2013 Category: Consumer Health News Tags: Cancer Medication Source Type: news

Anastrozole Halves Breast Cancer Incidence in High-Risk Postmenopausal Women (FREE)
By Amy Orciari Herman The aromatase inhibitor anastrozole cuts breast cancer incidence in half among high-risk postmenopausal women, according to an industry-supported trial in the Lancet.Nearly 4000 postmenopausal women at increased risk (e.g., … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 13, 2013 Category: Primary Care Source Type: news

Anastrozole Halves Breast Cancers in Prevention StudyAnastrozole Halves Breast Cancers in Prevention Study
Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 13, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Anastrozole reduces breast cancer chance by 53 percent, study says
A new study shows a drug to prevent breast cancer in high risk patients is not only more effective than current treatments, it also comes with far less serious side effects. Vinita Nair reports from New York. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - December 12, 2013 Category: Consumer Health News Source Type: news

anastrozole could HALVE risk of breast cancer in women with high risk
Taking the drug anastrozole for five years cuts the risk by 53 per cent, say researchers from Queen Mary University of London. (Source: the Mail online | Health)
Source: the Mail online | Health - December 12, 2013 Category: Consumer Health News Source Type: news

Drug Arimidex Cuts Risk for Breast Cancer in Older, High-Risk Women: Study
It could be welcome addition to other preventive meds such as tamoxifen, experts say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 12, 2013 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Oncology, Pharmacy, News, Source Type: news

Morning Break: Arimidex Gets Big Win, Fat Line Flat Lines
(MedPage Today) -- Health news and commentary from around the Web, gathered by the MedPage Today staff. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 12, 2013 Category: Hematology Source Type: news

Drug Arimidex Cuts Risk for Breast Cancer in Older, High-Risk Women
It could be welcome addition to other preventive meds such as tamoxifen, experts say Source: HealthDay Related MedlinePlus Pages: Breast Cancer, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - December 12, 2013 Category: Consumer Health News Source Type: news

Breast cancer drug 'halves likelihood of high-risk women developing disease'
Anastrozole must be made available on NHS immediately, say charities and authors of trial funded by Cancer Research UKA drug not yet available on the NHS has been found to be better at preventing breast cancer than those approved for use, leading to urgent calls for the National Institute for Health and Care Excellence to make it accessible immediately.The drug anastrozole has been found to halve the likelihood of high-risk women developing the disease and to have fewer side-effects, according to a study published on Thursday in the Lancet medical journal. The Ibis-II study, funded by Cancer Research UK and led by Queen Ma...
Source: Guardian Unlimited Science - December 12, 2013 Category: Science Authors: Alexandra Topping Tags: theguardian.com News Health Society Drugs The National Institute for Health and Care Excellence (Nice) UK news Breast cancer NHS Science Source Type: news

Arimidex Prevents First Breast Cancers (CME/CE)
SAN ANTONIO (MedPage Today) -- Anastrozole (Arimidex) reduced the risk of breast cancer by 53% in high-risk postmenopausal women, a primary prevention trial showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 12, 2013 Category: Hematology Source Type: news